Streetbeat News

Partnerships

CHTR

CZR

DIS

DKNG

PDYPY

WBD

The 2023 NFL season is kicking off with a game between the Buffalo Bills and New York Jets, with the game being broadcasted on ABC, ESPN, and ESPN+ (units of Walt Disney Co). Betting odds are provided by DraftKings Inc. Promotional offers for betting are available from FanDuel (a unit of Flutter Entertainment), Caesars Entertainment Inc, and PointsBet (acquired by Fanatics). The game also marks the end of a carriage dispute between Disney and Charter Communications Inc, allowing Charter customers access to ESPN. The Jets have gained media visibility through the NFL preseason docuseries “Hard Knocks,” which airs on Warner Bros. Discovery’s HBO and Max streaming platforms.

Portfolio Pulse from Chris Katje

September 11, 2023 | 6:52 pm

RSSS

Research Solutions, Inc. (RSSS) has partnered with Clinitech India to transform medical education. The details of the partnership and its potential impact on the companies' operations and revenues are not specified in the article.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 6:29 pm

CHTR

DIS

FUBO

FuboTV shares are trading lower following a report suggesting Disney and Charter are nearing a carriage deal.

Portfolio Pulse from Bill Haddad

September 11, 2023 | 6:09 pm

LMT

Poland's Ministry Of National Defense has signed a framework agreement with Lockheed Martin for the HOMAR-A Rocket Artillery System Program. Under the agreement, 486 HOMAR-A vehicles will be assembled in Poland, with first deliveries starting in 2026.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 5:44 pm

ILMN

JNJ

NVS

PFE

REGN

RHHBY

RXRX

Several publicly traded companies are integrating artificial intelligence (AI) into their operations to catalyze transformations in the biotech and pharmaceutical sectors. These companies include Recursion Pharmaceuticals (RXRX), 23andMe (ME), Novartis (NVS), Roche (RHHBY), Pfizer (PFE), Johnson & Johnson (JNJ), Regeneron Pharmaceuticals (REGN), and Illumina (ILMN). The integration of AI is expected to enhance drug discovery, patient care, and other operations.

Portfolio Pulse from Steve Macalbry

September 11, 2023 | 5:27 pm

VOD

Vodafone and Project Kuiper have announced a plan to extend connectivity in Africa and Europe, leading to a rise in Vodafone's share prices.

Portfolio Pulse from Bill Haddad

September 11, 2023 | 5:25 pm

FANG

Diamondback Energy Inc (FANG) has announced a joint venture with Five Point Energy LLC, named Deep Blue Midland Basin LLC. The 15-year deal involves FANG producing and supplying water in a 12-county area in the Midland Basin. FANG will hold a 30% stake in Deep Blue and has received upfront cash proceeds of around $500 million. Both companies plan to contribute $500 million in follow-on equity capital for future projects and acquisitions. Deep Blue has also secured long-term acreage dedications with two investment-grade customers.

Portfolio Pulse from Lekha Gupta

September 11, 2023 | 5:00 pm

DOTUSD

Alan Vey, CEO and founder of Aventus, a Polkadot parachain, has been recognized as one of the 30 people to watch in Web3. Aventus has been making significant strides in blockchain-based ticketing, with major partnerships including Vodafone's 'Economy of Things' Digital Asset Broker (DAB), Polkadot, Beatport, and Parity. Aventus was conceived as an open platform for NFTs, video games, loyalty programs, event ticketing, supply chain provenance, and cargo management. The online event ticketing market size is expected to grow from $77.49 billion in 2023 to $97.36 billion by 2028.

Portfolio Pulse from Justin Roberti

September 11, 2023 | 4:51 pm

GILD

MRK

Gilead Sciences Inc has revealed early data from its Phase 2 EVOKE-02 study evaluating Trodelvy, in combination with Merck & Co Inc's Keytruda, for the treatment of advanced or metastatic non-small cell lung cancer. The preliminary results, presented at the IASLC 2023 World Conference on Lung Cancer, showed promising response and disease control rates. Gilead entered into two clinical trial collaboration and supply agreements with Merck in January 2022 to evaluate the combination of Trodelvy and Keytruda.

Portfolio Pulse from Vandana Singh

September 11, 2023 | 4:45 pm

AMKR

HON